Q1 2021 financial results

Today we announce our financial results for the first quarter of 2021.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

LATEST NEWS

11 May, 2021 Corporate Release
Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is off to a good start
03 May, 2021 Press Release
New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder
03 May, 2021 Press Release
Nyt studie viser, at vortioxetin hjælper patienter med svær depression og komorbid generaliseret angst

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

Mohammad Sohail on working at Lundbeck

Cross-Cultural Leadership

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,600

employees supporting our purpose

1915

year Lundbeck was founded

A Strange Dream

A Small Caterpillar Taking Cover Under a Leaf